Efficient in vitro generation of hematopoietic stem cells (HSCs) from embryonic stem cells (ESCs) holds great promise for cell-based therapies of hematological diseases. To date, HoxB4 remains to be the most effective transcription factor (TF) whose overexpression in ESCs confers long-term repopulating ability to ESC-derived HSCs. Despite
INTRODUCTION
The variety of cells in a tissue is generated by multi-potent lineage-specific stem cells, which in turn are derived from pluripotent embryonic stem cells. Interest in ESCs has been greatly fuelled by their potential to generate cells for cell replacement therapy for a wide range of diseases. This has also been heightened by the advent of induced pluripotent stem cells where a somatic cell can be reprogrammed into an ESC-like state 1, 2 . In spite of these great promises, gene regulatory pathways controlling lineagespecific differentiation of ESCs are poorly understood, hindering efforts to derive, expand, and manipulate lineage-specific stem cells in vitro for therapeutic purposes.
The spontaneous generation of hematopoietic stem cells by differentiating ESCs has long been documented and characterized 3 . In most cases, ESC-derived HSCs show similar clonogenic progenitor capacity and primitive phenotype to somatic sources of hematopoietic progenitors, but possess limited in vivo repopulating capacity when transplanted into immunodeficient mice 4 . Thus, if ESCs are to be used for generating HSCs, we need to know much more about the genetic and epigenetic factors involved in the process in order to drive the undifferentiated ES cells accurately and efficiently down hematopoietic developmental pathways.
HoxB4 is a member of the highly conserved homeodomain transcription factor family. It was the first TF shown to lead to profound HSC expansion in vitro and in vivo when ectopically expressed in adult bone marrow cells and ESCs 5 . These HSCs fully replenish the stem cell pool of lethally irradiated mice and maintain a normal supply of HSCs and mature blood cells for the duration of life [6] [7] [8] . So far, collective findings strongly suggest that HoxB4-mediated ESC differentiation system recapitulates early
For personal use only. on November 16, 2017 . by guest www.bloodjournal.org From hematopoiesis observed in vivo during embryonic development 9, 10 . However, a recent study suggests that the precise control of HoxB4 expression level is important for in vivo HSC development 10 , providing a cautionary note for using in vitro models. Nevertheless, the HoxB4 system remains a powerful and convenient in vitro model to explore the molecular pathways that specify hematopoietic fate, which otherwise would be difficult to examine in embryos.
To date, the molecular mechanisms behind HoxB4-mediated HSC development are poorly understood. As a first effort to define the molecular pathways controlled by HoxB4, Schiedlmeier et al. 11 performed a genome-wide mRNA profiling of mouse ESCs over-expressing HoxB4. Based on differential gene expression, they identified roughly 700 genes that are likely direct targets of HoxB4. Those genes are involved in pathways important for controlling self-renewal, maintenance, and differentiation of stem cells.
More recently, using chromatin immunoprecipitation coupled with a promoter tiling microarray (ChIP-CHIP), two studies identified additional HoxB4 target genes in ESCderived HSCs 12 and in a primitive hematopoietic progenitor cell line, EML 13 . Taken together, these two pioneering studies expanded the set of HoxB4 targets to roughly 3,500. Nevertheless, two critical questions remain to be answered with regard to the HoxB4 regulatory network. First, a comprehensive set of HoxB4 direct targets still need to be established. Since previous studies only used promoter-tiling microarray, they likely missed many gene-distal HoxB4 binding sites. Indeed, based on a HoxB4 DNA motif scan of the mouse genome prior to this study, we found many thousands more putative HoxB4 binding sites than those identified by the previous ChIP-CHIP studies. Second, the dynamics of the HoxB4 regulatory network during the differentiation process has not 
METHODS

HoxB4 expression vector, ES cell line and culture condition.
Construction of the murine stem cell virus (MSCV)-based expression vector was described previously in 14 . In this vector, the human HoxB4 gene is under the control of transcriptional regulatory elements within the 5' LTR of the virus, resulting in constitutive expression of HoxB4. We are grateful to Dr. Hannes Klump (University of Essen, Germany) for providing the HoxB4-transduced CCE cells. Transduced cells were grown on gelatinized flasks in feeder cell-free ES cell culture medium consisting of DMEM (Invitrogen) supplemented with 15% fetal calf serum, 0.1 mM of L-glutamine, 100 U/mL penicillin, 100 g/mL streptomycin, and 1000 U/mL leukemia inhibitory factor.
The culture medium was changed daily, and the cells were passaged every 2 to 3 days to
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Differentiation of ES cells to hematopoietic cells
We adopted a 2-stage culture strategy as described previously 6, 7 . At day 0, HoxB4-transduced CCE ES cells were subjected to embryoid body (EB) formation over 6 days on non-hematopoietic differentiation medium. Briefly, ES cells were plated on an ultralow attachment Petri dish at a concentration of 2000 cells/mL in a methycellulose-based differentiation medium containing Iscove modified Dulbecco medium (Invitrogen), 15%
FCS, 300 μg/mL transferrin, 2 mM L-glutamine, 100 U/mL penicillin, 100 μg/mL streptomycin, 5% protein-free hybridoma medium (Invitrogen), 4x10 -4 M monothioglycerol, and 50 μg/mL ascorbic acid. At stage two, EBs were dissociated into single-cell suspension using trypsin (2.75%), and 3.5x10 6 cells/mL cells were re-plated on another ultra-low attachment Petri dish in a serum-free hematopoietic differentiation medium that contains StemPro34 plus nutrient supplement (Invitrogen) and a cocktail of hematopoietic cytokines including murine stem cell factor (mSCF,100 ng/mL; R&D Systems), mIL-3 (2 ng/mL), mIL-6 (5 ng/mL), Flt3-L (10 ng/mL), insulin-like growth factor-1 (IGF-1; 40 ng/mL; Promega, Madison, WI), and dexamethasone (1 μM; SigmaAldrich). Culture medium was changed every other day and cell density maintained below 4x10 6 cells/mL.
Chromatin immunoprecipitation coupled with deep sequencing (ChIP-Seq)
We conducted ChIP-Seq experiments using cells from days 6, 16 
Validation of HoxB4 ChIP-Seq peaks using ChIP-qPCR
Cell culture and ChIP were conducted in the same way as in the ChIP-Seq experiments.
After the ChIP step, purified DNA from matched IP sample and input control sample were subjected to quantitative polymerase chain reaction (qPCR) analysis using SYBR green chemistry (Invitrogen). QPCR primers were designed to flank selected HoxB4 peak 
∆
Ct is the cycle number difference between a sample and a GAPDH control.
Gene Expression Microarray Experiments
Affymetrix mouse gene ST 1.0 microarray was used to profile mRNA expression levels at days 0, 6, 16, and 26 during the differentiation process. The microarray platform covers 28,853 well-annotated mouse genes. Three biological replicates were performed for each time point. Microarray data were normalized using the RMA algorithm 15 .
Differentially expressed genes were detected using the Limma algorithm 16 .
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RESULTS
Differentiation of ESC to hematopoietic cells by over-expression of HoxB4
We previously developed a protocol for deriving HSCs from murine ESCs by the combination of HoxB4 over-expression and incubation with hematopoietic cytokines 
Genome-wide HoxB4 location maps during ESC differentiation to hematopoietic cells
To understand the mechanisms by which HoxB4 mediates ESC differentiation to HSCs, we used ChIP-Seq to identify direct targets of HoxB4 at days 6, 16, and 26 of the differentiation process. A ChIP-grade rabbit monoclonal antibody against HoxB4 protein was used and antibody specificity was confirmed by Western blot (supplemental Figure   For personal use only. on November 16, 2017 . by guest www.bloodjournal.org From 1A). On average, 8.9 million sequencing reads were obtained for each time point and 67% of all reads were uniquely mapped to the mouse genome (supplemental Table 1 ).
Using a false discovery rate (FDR) of 1%, we identified 3632, 7232, 29313 genomic loci bound by HoxB4 at the three time points, respectively (supplemental Methods, Figure   1A , supplemental Table 2 ). The median fold enrichment of read count within identified peaks is 11, 11, and 14, respectively (supplemental Figure 2) . Among the set of binding sites, 600 are shared by all three time points. Genes near these common sites are enriched for TFs (p value = 8.2x10 -4 ) . A PubMed literature survey shows that many of these TFs are involved in hematopoiesis (supplemental Table 3 ), suggesting that HoxB4 is a master regulator of hematopoiesis.
Next, we used ChIP coupled with quantitative PCR (ChIP-qPCR) to assess the quality of our ChIP-Seq data. We randomly selected 30 called peaks (10 peaks/time point) and achieved a validation rate of 83% (supplemental Figure 3) , demonstrating excellent corroboration of our ChIP-Seq data. We also examined the overlaps between our peaks and peaks from previous ChIP-CHIP studies. Lee et al. 13 . In summary, extensive quality assessment demonstrates that we have generated a high quality data set of HoxB4 binding sites across the time course of ESC-to-HSC differentiation.
Dynamic gene expression program during ESC differentiation to hematopoietic cells
To examine the dynamics of the transcriptome of the differentiating ESCs, we profiled mRNA expression levels of day 0, 6, 16, and 26 cells. At a FDR of 0.5%, we found 5,780
genes that are differentially expressed between two adjacent time points, representing roughly 20% of all genes in the mouse genome. For individual time periods, 1,665, 3,947
and 2,068 genes were differentially expressed during the three consecutive periods, respectively (supplemental Table 4 ). Among the differentially expressed genes, 60.6%, 51.4%, and 41.1% were up-regulated during the three periods, respectively (supplemental . In total, we identified 31 TF genes that were both differentially targeted by HoxB4 and exhibited differential expression between adjacent time points ( Figure 4A) Figure 4A ). For instance, Id2, Rb1, Pbx1, Eomes, and
Ctnnb1 were up-regulated during the initial phase of ESC differentiation to hematopoietic cells followed by down-regulation. In contrast, Foxp1 was down-regulated initially followed by up-regulation. Such complicated regulatory patterns suggest that the activities of the regulated TFs need to be carefully controlled during the developmental processes. Thus, these regions represent putative transcriptional enhancers whose hallmarks include combinatorial action of multiple TFs. Next, we asked whether the frequency of TF pair colocalization in the same regions was greater than would be expected by chance, thus indicating potential co-regulatory activities (see Methods for details). Our analysis revealed four TFs that have statistically significant binding site overlap (p < 0.001) with HoxB4. They are, in decreasing order of overlap significance, Runx1, Meis1, Scl and Fli1 ( Figure 5A ).
Among the four TFs, Scl, Lyl1, and Runx1 are known to bind as components of multiprotein complexes to enhancers 37 characterization of the other newly discovered TF interactions should lead to insights into the combinatorial regulation of hematopoietic pathway genes. Figure 5C shows a breakdown of the putative enhancer classes based on their participating TFs. The largest class are enhancers containing both HoxB4 and Fli1 (HF class). This is not surprising given that Fli1 has the largest number of peaks in the genome. However, the enhancer class that contains all five TFs (HFMRS class) is surprisingly abundant, even more so compared to classes that contain fewer TFs (e.g.
HFRS and HFMR classes). The genes targeted by different classes of enhancers are
enriched for distinct functions ( Figure 5D ). For instance, HFMS enhancers target genes involved in lymphocyte proliferation whereas HFMRS and HM enhancers target genes involved in hematopoietic/lymphoid organ development. This set of enhancer targets represents a rich source of potentially new mediators of HSC development.
Many genes down-regulated in lymphoid-biased HSCs are HoxB4 targets
A drawback of the HoxB4-mediated development of HSCs is that the resulting HSCs have impaired lymphoid lineage developmental potential 5, [39] [40] [41] . By comparing the gene expression profiles of ESC-derived HSCs and HSCs isolated from adult bone marrow we expect to gain insights into the molecular mechanisms for this deficiency. To this end, we compared genome-wide expression profiles of four types of HSCs: ESC-derived HSCs based on HoxB4 over-expression; whole HSCs isolated from adult bone marrow without distinction of subtypes 27 ; and two subtypes of HSCs, myeloid-biased HSCs (My-HSCs) and lymphoid biased HSCs (Ly-HSCs) 42 . Furthermore, for ESC-derived HSCs, we used cells from two independently studies, our day 26 cells and those generated by Oshima et al. using a similar HoxB4-based protocol 12 . Global gene expression correlation is 1 7 moderate between adult HSCs and ESC-derived HSCs (supplemental Figure 6) 42 identified 785 genes that are differentially expressed in one of the HSC subtypes, including 434 genes expressed higher in My-HSCs and 351 genes expressed higher in Ly-HSCs. Next, we focused on this set of lineage-biased genes in order to understand mechanisms underlying the bias against lymphoid lineage in ESCderived HSCs.
As shown in Figure 6A , the expression profile of these lineage-biased genes in our ESC-derived HSCs was more similar to that in My-HSCs than that in Ly-HSCs. This observation prompted us to compare the absolute expression levels of these genes in the different cell types. After quantile normalization of the microarray data to account for variations due to non-biological factors. We found that genes up-regulated in adult MyHSCs (compared to Ly-HSCs) were expressed at similar levels in day-26 cells ( Figure   6B ). In stark contrast, genes up-regulated in adult Ly-HSCs were expressed at significantly lower levels in day-26 cells compared to both My-HSCs and Ly-HSCs ( Figure 6C ). This result suggests that a failure to prime the lymphoid lineage gene 1 8 expression program may be the cause of the developmental defect of the lymphoid lineage from ESC-derived HSCs.
One hundred eighty four Ly-HSC genes were expressed at least two-fold lower in our day-26 cells than in Ly-HSCs, with an average fold decrease of 7.9 (supplemental Table 5 ). Strikingly, the majority of these down-regulated genes (157/184) were targeted by HoxB4 based on our day 26 ChIP-Seq data (supplemental Table 5 ). Further, 63.9% of the HoxB4 sites targeting the downregulated genes overlap with one or more of the four TFs, Fli1, Meis1, Runx1, and Scl. In comparison, the fraction of combinatorial sites among all day 26 HoxB4 sites is 26.2% (p value = 0, one-sample proportion test).
Therefore, our data suggests that combinatorial regulation plays an important role in the down-regulation of these Ly-HSC genes.
The down-regulated genes were enriched for lysosomal and mitochondrial functions ( Table 1) Understanding the dynamics of transcriptional regulatory networks is essential for gaining insights into hematopoiesis. Work described here represents the first study of the dynamics of the HoxB4 regulatory network during ESC differentiation to hematopoietic
cells. An unexpected finding from our study is that the pool of HoxB4 targets appears to Consistent with previous ChIP-CHIP studies 12, 13 , our data suggest that HoxB4 is a master regulator of ESC differentiation to HSCs. By combining gene expression and
ChIP-Seq data, we identified multiple essential hematopoietic TFs and epigenetic factors that are direct targets of HoxB4 (Figure 4 ). Among these regulators, roles of the epigenetic factors in early hematopoiesis are much less understood compared to the TFs.
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